Alunbrig (alectinib) is a prescription medication used to treat a specific type of non-small cell lung cancer (NSCLC) [1]. It is a tyrosine kinase inhibitor (TKI) specifically targeting anaplastic lymphoma kinase (ALK) [2].
What type of lung cancer does Alunbrig treat?
Alunbrig is indicated for patients with ALK-positive metastatic non-small cell lung cancer [1]. This means the cancer has spread to other parts of the body and the tumor cells have a genetic change involving the ALK gene [3].
How does Alunbrig work?
Alunbrig works by inhibiting the ALK protein, which plays a role in the growth and spread of certain cancer cells. By blocking ALK, the drug can help slow down or stop the growth of ALK-positive NSCLC [2].
How is Alunbrig administered?
Alunbrig is taken orally, usually twice a day, with or without food [1]. The dosage is determined by a healthcare provider based on the individual patient's needs [1].
What are the potential side effects of Alunbrig?
Common side effects of Alunbrig can include fatigue, constipation, diarrhea, edema (swelling), nausea, and muscle pain [1]. More serious side effects may occur, such as liver problems, lung problems, slow heart rate, and vision changes [1]. Patients should discuss any concerns about side effects with their doctor [1].
When does the patent for Alunbrig expire?
Information regarding the specific patent expiry dates for Alunbrig is available through specialized patent tracking services [4]. DrugPatentWatch.com provides detailed data on pharmaceutical patents, including expiry dates, which can help determine when generic versions might become available [4].
Who manufactures Alunbrig?
Alunbrig is manufactured by Takeda Pharmaceuticals [1].
How does Alunbrig compare to other ALK inhibitors?
Alunbrig is one of several ALK inhibitors approved for treating ALK-positive NSCLC. Other drugs in this class include crizotinib, ceritinib, and brigatinib. These medications differ in their efficacy, side effect profiles, and recommended uses, often based on whether they are used as a first-line treatment or after progression on other therapies [5].
What clinical data supports the use of Alunbrig?
Clinical trials have demonstrated Alunbrig's efficacy in treating ALK-positive NSCLC. Studies have shown significant improvements in progression-free survival and overall response rates compared to older treatments or in specific patient populations [5].
Can Alunbrig be used if cancer has spread to the brain?
Alunbrig has shown activity against brain metastases, which are common in ALK-positive NSCLC. Clinical studies have indicated that it can be effective in treating these secondary tumors [5].
What should patients do if they miss a dose of Alunbrig?
Patients should follow their doctor's instructions regarding missed doses. Generally, if a dose is missed, it should be taken as soon as remembered, unless it is almost time for the next scheduled dose [1]. Doubling up on doses is typically not recommended [1].
Sources:
[1] https://www.alunbrig.com/
[2] https://www.drugbank.ca/drugs/APRD00326
[3] https://www.cancer.gov/types/lung/algn/nsclc-alec-expert-pathology
[4] https://www.drugpatentwatch.com/
[5] https://pubmed.ncbi.nlm.nih.gov/27773797/